The hTERT promoter enhances the antitumor activity of an oncolytic adenovirus under a hypoxic microenvironment

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Hashimoto, Yuuri ^a   Tazawa, Hiroshi ^a,b   Teraishi, Fuminori ^a   Kojima, Toru ^a   Watanabe, Yuichi ^a   Uno, Futoshi ^a   Yano, Shuya ^a   Urata, Yasuo ^c   Kagawa, Shunsuke ^a   Fujiwara, Toshiyoshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c National Institute of Infectious Diseases   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; E1A PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; OBP 301; ONCOLYTIC ADENOVIRUS; ONCOLYTIC ADENOVIRUS 5; ONCOLYTIC VIRUS; TELOMELYSIN; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CANCER CELL CULTURE; CELL HYPOXIA; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFECT; FEMALE; GENE; GENE ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TELOMERASE REVERSE TRANSCRIPTASE GENE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; UPREGULATION; VIRUS REPLICATION; WILD TYPE;

ADENOVIRIDAE; CELL HYPOXIA; HUMANS; ONCOLYTIC VIROTHERAPY; PROMOTER REGIONS, GENETIC; TELOMERASE; TUMOR MICROENVIRONMENT;

EID: 84862488593     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039292     Document Type: Article

References (46)

1. Majmundar AJ, Wong WJ, Simon MC, (2010) Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 40: 294-309.
2. Wilson WR, Hay MP, (2011) Targeting hypoxia in cancer therapy. Nat Rev Cancer 11: 393-410.
3. Höckel M, Vaupel P, (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93: 266-276.
4. Bertout JA, Patel SA, Simon MC, (2008) HYPOXIA AND METABOLISM SERIES - TIMELINE The impact of O-2 availability on human cancer. Nature Reviews Cancer 8: 967-975.
5. Harrison L, Blackwell K, (2004) Hypoxia and anemia: Factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 9: 31-40.
6. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, et al. (2008) Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10: 295-305.
7. Yoo YG, Christensen J, Gu J, Huang LE, (2011) HIF-1{alpha} Mediates Tumor Hypoxia to Confer a Perpetual Mesenchymal Phenotype for Malignant Progression. Sci Signal 4: pt4.
8. Keith B, Simon MC, (2007) Hypoxia-inducible factors, stem cells, and cancer. Cell 129: 465-472.
9. Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, et al. (2010) Hypoxia inducible factors in cancer stem cells. Br J Cancer 102: 789-795.
10. Li Z, Bao S, Wu Q, Wang H, Eyler C, et al. (2009) Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15: 501-513.
11. Chang CJ, Yang JY, Xia W, Chen CT, Xie X, et al. (2011) EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell 19: 86-100.
12. Tredan O, Galmarini CM, Patel K, Tannock IF, (2007) Drug resistance and the solid tumor microenvironment. Journal of the National Cancer Institute 99: 1441-1454.
13. Kirn D, Martuza RL, Zwiebel J, (2001) Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 7: 781-787.
14. Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, et al. (2004) Telomerase-specific replication-selective virotherapy for human cancer. Clinical Cancer Research 10: 285-292.
15. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, et al. (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015.
16. Shay JW, Wright WE, (1996) Telomerase activity in human cancer. Curr Opin Oncol 8: 66-71.
17. Nakayama J, Tahara H, Tahara E, Saito M, Ito K, et al. (1998) Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 18: 65-68.
18. Umeoka T, Kawashima T, Kagawa S, Teraishi F, Taki M, et al. (2004) Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene. Cancer Research 64: 6259-6265.
19. Hashimoto Y, Watanabe Y, Shirakiya Y, Uno F, Kagawa S, et al. (2008) Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus. Cancer Science 99: 385-390.
20. Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, et al. (2010) A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther 18: 429-434.
21. Pouysségur J, Dayan F, Mazure NM, (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441: 437-443.
22. Ke Q, Costa M, (2006) Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 70: 1469-1480.
23. Nishi H, Nakada T, Kyo S, Inoue M, Shay JW, et al. (2004) Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT). Molecular and Cellular Biology 24: 6076-6083.
24. Yatabe N, Kyo S, Maida Y, Nishi H, Nakamura M, et al. (2004) HIF-1-mediated activation of telomerase in cervical cancer cells. Oncogene 23: 3708-3715.
25. Anderson CJ, Hoare SF, Ashcroft M, Bilsland AE, Keith WN, (2006) Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. Oncogene 25: 61-69.
26. Pipiya T, Sauthoff H, Huang YQ, Chang B, Cheng J, et al. (2005) Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression. Gene Ther 12: 911-917.
27. Shen BH, Hermiston TW, (2005) Effect of hypoxia on Ad5 infection, transgene expression and replication. Gene Ther 12: 902-910.
28. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, et al. (1997) Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320-1323.
29. Guo ZS, (2011) The impact of hypoxia on oncolytic virotherapy. Virus Adaptation and Treatment 3: 71-82.
30. Hernandez-Alcoceba R, Pihalja M, Qian D, Clarke MF, (2002) New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum Gene Ther 13: 1737-1750.
31. Post DE, Van Meir EG, (2003) A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 22: 2065-2072.
32. Kwon OJ, Kim PH, Huyn S, Wu L, Kim M, et al. (2010) A hypoxia- and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas. Clin Cancer Res 16: 6071-6082.
33. Küster K, Koschel A, Rohwer N, Fischer A, Wiedenmann B, et al. (2010) Downregulation of the coxsackie and adenovirus receptor in cancer cells by hypoxia depends on HIF-1alpha. Cancer Gene Ther 17: 141-146.
34. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR, (1993) Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73: 309-319.
35. Cowden Dahl KD, Robertson SE, Weaver VM, Simon MC, (2005) Hypoxia-inducible factor regulates alphavbeta3 integrin cell surface expression. Mol Biol Cell 16: 1901-1912.
36. Niu JX, Zhang WJ, Ye LY, Wu LQ, Zhu GJ, et al. (2007) The role of adhesion molecules, alpha v beta 3, alpha v beta 5 and their ligands in the tumor cell and endothelial cell adhesion. Eur J Cancer Prev 16: 517-527.
37. Kizaka-Kondoh S, Konse-Nagasawa H, (2009) Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia. Cancer Sci 100: 1366-1373.
38. Lacher MD, Tiirikainen MI, Saunier EF, Christian C, Anders M, et al. (2006) Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and Adenovirus Receptor in conjunction with reversal of epithelial-mesenchymal transition. Cancer Res 66: 1648-1657.
39. Lacher MD, Shiina M, Chang P, Keller D, Tiirikainen MI, et al. (2011) ZEB1 limits adenoviral infectability by transcriptionally repressing the coxsackie virus and adenovirus receptor. Mol Cancer 10: 91.
40. Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Kondo S, et al. (2007) Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst 99: 1410-1414.
41. Eriksson M, Guse K, Bauerschmitz G, Virkkunen P, Tarkkanen M, et al. (2007) Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells. Mol Ther 15: 2088-2093.
42. Zhang X, Komaki R, Wang L, Fang B, Chang JY, (2008) Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin Cancer Res 14: 2813-2823.
43. Short JJ, Curiel DT, (2009) Oncolytic adenoviruses targeted to cancer stem cells. Mol Cancer Ther 8: 2096-2102.
44. Hiyama E, Hiyama K, (2007) Telomere and telomerase in stem cells. Br J Cancer 96: 1020-1024.
45. Castelo-Branco P, Zhang C, Lipman T, Fujitani M, Hansford L, et al. (2011) Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition. Clin Cancer Res 17: 111-121.
46. Bauerschmitz GJ, Ranki T, Kangasniemi L, Ribacka C, Eriksson M, et al. (2008) Tissue-specific promoters active in CD44+CD24-/low breast cancer cells. Cancer Res 68: 5533-5539.